| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ST2 |
| Uniprot No | Q01638 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-323aa |
| 氨基酸序列 | KFSKQSWGLENEALIVRCPRQGKPSYTVDWYYSQTNKSIPTQERNRVFAS GQLLKFLPAAVADSGIYTCIVRSPTFNRTGYANVTIYKKQSDCNVPDYLM YSTVSGSEKNSKIYCPTIDLYNWTAPLEWFKNCQALQGSRYRAHKSFLVI DNVMTEDAGDYTCKFIHNENGANYSVTATRSFTVKDEQGFSLFPVIGAPA QNEIKEVEIGKNANLTCSACFGKGTQFLAAVLWQLNGTKITDFGEPRIQQ EEGQNQSFSNGLACLDMVLRIADVKEEDLLLQYDCLALNLHGLRRHTVRL SRKNP |
| 预测分子量 | 61 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ST2重组蛋白的3篇代表性文献摘要概述：
---
1. **标题**：*Interleukin-33 and the ST2 receptor in immunity and fibrosis*
**作者**：Liew, F.Y., et al.
**摘要**：该综述探讨了ST2(IL-33受体)在免疫调节及纤维化中的作用，指出重组ST2蛋白可通过结合IL-33抑制Th2型炎症反应，并在实验模型中减少器官纤维化进展。
2. **标题**：*Soluble ST2 as a biomarker for cardiac disease*
**作者**：Weinberg, E.O., et al.
**摘要**：研究利用重组可溶性ST2蛋白建立检测方法，发现其在心衰患者血清中水平升高，提示其作为心肌应激和纤维化的生物标志物潜力，可用于预后评估。
3. **标题**：*Expression and purification of recombinant ST2 extracellular domain in E. coli*
**作者**：Tominaga, S., et al.
**摘要**：报道了通过大肠杆菌系统高效表达重组ST2胞外域蛋白的方法，验证其与IL-33的结合活性，为后续功能研究及抗体开发提供可靠蛋白来源。
---
这些文献分别从分子机制、临床应用及重组制备技术角度解析了ST2蛋白的特性。
**Background of ST2 Recombinant Protein**
ST2. also known as interleukin-1 receptor-like 1 (IL1RL1), is a member of the interleukin-1 receptor (IL-1R) family. It exists in two primary isoforms: a transmembrane receptor (ST2L) and a soluble decoy receptor (sST2). ST2L binds to its ligand, interleukin-33 (IL-33), triggering signaling pathways that regulate immune responses, particularly in Th2 cells, mast cells, and macrophages. In contrast, sST2 acts as a decoy receptor, sequestering IL-33 and dampening ST2L-mediated signaling. This dual role makes the ST2/IL-33 axis critical in balancing pro-inflammatory and anti-inflammatory processes.
The recombinant ST2 protein is engineered for research and therapeutic applications. Produced via recombinant DNA technology in systems like *E. coli* or mammalian cell cultures, it retains the functional properties of native sST2. Recombinant ST2 is widely used to study mechanisms underlying immune regulation, fibrosis, and cardiovascular diseases. Elevated sST2 levels in serum correlate with adverse outcomes in heart failure, myocardial fibrosis, and inflammatory conditions like asthma, making it a biomarker of interest in clinical diagnostics.
In cardiology, sST2 has gained attention as a prognostic marker for heart failure. It is independent of traditional biomarkers (e.g., BNP) and reflects myocardial stress and fibrosis. Commercially available assays (e.g., Presage® ST2 assay) measure sST2 to stratify patient risk and guide therapy. Beyond diagnostics, recombinant ST2 is explored therapeutically to modulate IL-33 signaling in autoimmune diseases and fibrosis.
Overall, ST2 recombinant protein serves as a vital tool for understanding IL-33/ST2 biology and developing targeted therapies, bridging basic research and clinical applications.
×
